In this study, we investigated the effect of diet supplementation with sodium butyrate (5% w/w), a short-chain fatty acid produced by the intestinal microbiota, on metabolic parameters, body adiposity, hepatic and pancreatic lipid accumulation, beta cell function/mass as well as on the structure and function of the tight junction-mediated intestinal epithelial barrier in both normal and obese/prediabetic C57 mice fed a regular (control) or high-fat diet for 60 days, respectively. Butyrate treatment significantly inhibited all the high-fat-induced metabolic dysfunctions evaluated, i.e. significantly reduced the weight gain and body adiposity as well as the insulin resistant state, hyperglycemia and hyperinsulinemia, without changing food intake. In addition, high-fat-fed mice treated with this short-chain fatty acid displayed no compensatory hyperplasia of pancreatic beta cells nor marked hepatic steatosis as seen in prediabetic mice after high-fat diet only. Isolated pancreatic islets from high-fat-fed mice treated with butyrate showed improvement of the insulin secretion, which was associated with a significant decrease in lipid accumulation within the pancreas. Butyrate enhanced the intestinal epithelial barrier, as revealed by the FITC-Dextran permeability assay, which was accompanied by a significant increase in the junctional content of the tight junction-associated claudin-1 in intestinal epithelia of jejunum, ileum, and colon of both control and high-fat mice. In conclusion, our results showed that diet supplementation with butyrate inhibits the deleterious effects of high-fat diet intake on metabolic parameters and structure/function of several tissues/organs associated with type 2 diabetes mellitus in a mouse model, suggesting a potential use of this short-chain fatty acid in the treatment of this endocrine-metabolic disorder.
Impact statement
Butyrate is a short-chain fatty acid produced by the intestinal microbiota through the fermentation of non-absorbable carbohydrates and proteins (e.g. fibers). Sodium butyrate incorporated into the diet displayed a protective action on metabolic, hepatic, pancreatic and intestinal alterations induced by high-fat diet in mice, resulting in significant inhibition of the development of a prediabetic state. Thus, our data suggest that butyrate may have a potential therapeutic use in the treatment of type 2 diabetes and related disorders.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care2014; 37: 81–90.
2.
ThomasCCPhilipsonLH. Update on diabetes classification. Med Clin North Am2015; 99: 1–16.
3.
CanivellSGomisR. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev2014; 13: 403–7.
4.
OlokobaABObateruOAOlokobaLB. Type 2 diabetes mellitus: a review of current trends. Oman Med J2012; 27: 269–73.
5.
TripathyDChavezAO. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep2010; 10: 184–91.
6.
LeeBCLeeJ. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta2014; 1842: 446–62.
7.
BjörnholmMZierathJR. Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes. Biochem Soc Trans2005; 33: 354–7.
8.
WilcoxG. Insulin and insulin resistance. Clin Biochem Rev2005; 26: 19–39.
9.
ForbesJMCooperME. Mechanisms of diabetic complications. Physiol Rev2013; 93: 137–88.
10.
LinYBergAHIyengarPLamTKTGiaccaACombsTPRajalaMWDuXRollmanBLiWHawkinsMBarzilaiNRhodesCJFantusIGBrownleeMSchererPE. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem2005; 280: 4617–26.
11.
GhaisasSMaherJKanthasamyA. Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther2015; 158: 52–62.
12.
CaniPDOstoMGeurtsLEverardA. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes2012; 3: 4: 279–88.
13.
AmarJSerinoMLangeCChaboCIacovoniJMondotSLepagePKloppCMarietteJBouchezOPerezLCourtneyMMarreMKloppPLantieriODoréJCharlesMBalkauBBurcelinR. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia2011; 54: 3055–61.
14.
De KortSKeszthelyiDMascleeAAM. Leaky gut and diabetes mellitus: what is the link?Obes Rev2011; 12: 449–58.
15.
PrentkiMNolanCJ. Islet beta cell failure in type 2 diabetes. J Clin Invest2006; 116: 1802–12.
16.
RhodesCJ. Type 2 diabetes - a matter of β-cell life and death?Science2005; 307: 380–4.
17.
SoneHKagawaY. Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice. Diabetologia2005; 48: 58–67.
18.
Collares-Buzato CB. High-fat diets and β-cell dysfunction: molecular aspects. In: Mauricio D (eds) Molecular nutrition and diabetes. San Diego, USA: Elsevier, 2015, pp.115–130.
19.
OliveiraRBMaschioDACarvalhoCPFCollares-BuzatoCB. Influence of gender and time diet exposure on endocrine pancreas remodeling in response to high fat diet-induced metabolic disturbances in mice. Ann Anat2015; 200: 88–97.
20.
OliveiraRBCarvalhoCPFPoloCCDorighelloGGBoscheroACOliveiraHCFCollares-BuzatoCB. Impaired compensatory beta-cell function and growth in response to high-fat diet in LDL receptor knockout mice. Int J Exp Pathol2014; 95: 296–308.
21.
Gómez-DummLASeminoMCGagliardinoJJ. Sequential morphological changes in pancreatic islets of spontaneously diabetic rats. Pancreas1990; 5: 533–9.
22.
CaniPDBibiloniRKnaufCNeyrinckAMDelzenneNM. Changes in gut microbiota control metabolic diet–induced obesity and diabetes in mice. Diabetes2008; 57: 1470–81.
23.
CaniPDNeyrinckAMFavaFKnaufCBurcelinRGTuohyKMGibsonGRDelzenneNM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia2007; 50: 2374–83.
24.
Al-SalamiHButtGFawcettJPTuckerIGGolocorbin-KonSMikovM. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet2008; 33: 101–6.
25.
BosiEMolteniLRadaelliMGFoliniLFermoIBazzigaluppiEPiemontiLPastoreMRParoniR. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia2006; 49: 2824–7.
26.
NeuJReverteCMMackeyADLiboniKTuhacek-tenaceLMHatchMLiNCaicedoRASchatzDAAtkinsonM. Changes in intestinal morphology and permeability in the BioBreeding rat before the onset of type 1 diabetes. J Pediatr Gatroenterol Nutr2005; 40: 589–95.
27.
MeddingsJBJarandJUrbanskiSJHardinJGallDG. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol1999; 276: G951–7.
28.
MatsuzakiTNagataYKadoSUchidaKKatoIHashimotoSYokokuraT. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS1997; 105: 643–9.
ChangPVHaoLOffermannsSMedzhitovR. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci2014; 111: 2247–52.
31.
LiHPChenXLiMQ. Butyrate alleviates metabolic impairments and protects pancreatic beta cell function in pregnant mice with obesity. Int J Clin Exp Pathol2013; 6: 1574–84.
32.
HamerHMJonkersDVenemaKVanhoutvinSTroostFJBrummerRJ. The role of butyrate on colonic function. Aliment Pharmacol Ther2008; 27: 104–19.
33.
InanMSRasoulpourRJYinLHubbardAKRosenbergDWGiardinaC. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology2000; 118: 724–34.
34.
WangHBWangPYWangXWanYLLiuYC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci2012; 57: 3126–35.
35.
KhanSJenaG. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin. Chem Biol Interact2016; 254: 124–34.
36.
KhanSJenaGB. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Chem Biol Interact2014; 213: 1–12.
37.
DudakovicAEvansJMLiYMiddhaSMcGee-LawrenceMEVan WijnenAJWestendorfJJ. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J Biol Chem2013; 288: 28783–91.
38.
CananiRBCostanzoM DiLeoneLPedataMMeliRCalignanoA. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol2011; 17: 1519–28.
39.
GaoZYinJZhangJWardREMartinRJLefevreMCefaluWTYeJ. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes2009; 58: 1509–17.
40.
FalcãoVTFLMaschioDAde FontesCCOliveiraRBSantos-SilvaJCAlmeidaACSVanzelaECCartaxoMTCarvalhoCPFCollares-BuzatoCB. Reduced insulin secretion function is associated with pancreatic islet redistribution of cell adhesion molecules (CAMs) in diabetic mice after prolonged high-fat diet. Histochem Cell Biol2016; 146: 13–31.
41.
CarvalhoCPFOliveiraRBBritanASantos-SilvaJCBoscheroACMedaPCollares-BuzatoCB. Impaired β-cell-β-cell coupling mediated by Cx36 gap junctions in prediabetic mice. Am J Physiol Endocrinol Metab2012; 303: E144–51.
42.
KimAMillerKJoJKilimnikGWojcikPHaraM. Islet architecture: a comparative study. Islets2009; 1: 129–36.
43.
Catta-PretaMMendoncaLSFraulob-AquinoJAguilaMBMandarim-de-LacerdaCA. A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch2011; 459: 477–85.
44.
CastroAVBKolkaCMKimSPBergmanRNSinaiCAngelesL. Obesity, insulin resistance and comorbidities – mechanisms of association. Arq Bras Endocrinol Metab2015; 58: 600–9.
JohnsonAMFCostanzoAGareauMGArmandoAMQuehenbergerOJamesonJMOlefskyJM. High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability. PLoS One2015; 10: e0122195–e0122195.
47.
LarsenNVogensenFKVan Den BergFWJNielsenDSAndreasenASPedersenBKAbu Al-SoudWSørensenSJHansenLHMogensJakobsenM. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One2010; 5: e9085–e9085.
48.
SuzukiTHaraH. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab2010; 7: 19–19.
DanknerRChetritAShanikMHRazIRothJ. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabs Care2009; 32: 1464–6.
54.
WeyerCFoleyJEBogardusCTataranniPAPratleyRE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia2000; 43: 1498–506.
55.
AsgharZYauDChanFLeRoithDChanCBWheelerMB. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia2006; 49: 90–9.
56.
KatoSIshidaHTsuuraYTsujiKNishimuraMHorieMTaminatoTIkeharaSOdakaHIkedaIOkadaYSeinoY. Alterations in basal and glucose-stimulated voltage-dependent Ca2+ channel activities in pancreatic beta cells of non-insulin-dependent diabetes mellitus GK rats. J Clin Invest1996; 97: 2417–25.
57.
NagarajVKazimAHelgesonJLewoldCBarikSBudaPReinbotheTMWennmalmSZhangERenströmE. Elevated basal insulin secretion in type 2-diabetes caused by reduced plasma membrane cholesterol. Mol Endocrinol2016; 30: 1059–69.
58.
PinnickKECollinsSCLondosCGauguierDClarkAFieldingBA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity2008; 16: 522–30.
59.
ValladaresRSankarDLiNWilliamsELaiKKAbdelgelielASGonzalezCFWasserfallCHLarkinJIIISchatzDMarkAAtkinsonASTriplettEWNeuJLorcaGL. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One2010; 5: e10507–e10507.
60.
SaponeADe MagistrisLPietzakMClementeMGTripathiACuccaFLampisRKryszakDCartenìMGenerosoMIafuscoDPriscoFLaghiFRieglerGCarratuRCountsDFasanoA. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes2006; 55: 1443–9.
61.
FasanoA. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev2011; 91: 151–75.
Van ItallieCMAndersonJM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol2014; 36: 157–65.
64.
KrugSMSchulzkeJDFrommM. Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol2014; 36: 166–76.
65.
FuruseM. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol2010; 2: a002907–a002907.
66.
MukizaCNDubreuilDJ. Escherichia coli heat-stable toxin b impairs intestinal epithelial barrier function by altering tight junction proteins. Infect Immun2013; 81: 2819–27.
67.
CaoMWangPSunCHeWWangF. Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One2013; 8: e61944–e61944.
68.
HortonFWrightJSmithLHintonPJRobertsonMD. Increased intestinal permeability to oral chromium (51Cr) -EDTA in human Type 2 diabetes. Diab Med2014; 31: 559–63.
69.
DingSChiMMScullBPRigbyRSchwerbrockNMJMagnessSJobinCLundPK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One2010; 5: e12191–e12191.
70.
HuangCSongPFanPHouCThackerPMaX. Dietary Sodium butyrate decreases postweaning diarrhea by modulating intestinal permeability and changing the bacterial communities in weaned piglets. J Nutr2015; 21: 2274–80.
71.
KumarMSongH-JChoS-KBalasubramanianSChoeS-YRhoG-J. Effect of histone acetylation modification with sodium butyrate, a histone deacetylase inhibitor, on cell cycle, apoptosis, ploidy and gene expression in porcine fetal fibroblasts. J Reprod Dev2007; 53: 903–13.
72.
LuoHMDuMHLinZLZhangLMaLWangHWen YuWLvYLuJ-YPiY-LHuSShengZ-Y. Valproic acid treatment inhibits hypoxia-inducible factor 1α accumulation and protects against burn-induced gut barrier dysfunction in a rodent model. PLoS One2013; 8: e77523–e77523.
73.
VinkenMDe RopEDecrockEDe VuystELeybaertLVanhaeckeTRogiersV. Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet?Biochim Biophys Acta2009; 1795: 53–61.
